Last reviewed · How we verify
FLUDEOXYGLUCOSE F 18
Fludeoxyglucose F-18 is a glucose analog that accumulates in cells with high glucose metabolism, reflecting metabolic activity.
At a glance
| Generic name | FLUDEOXYGLUCOSE F 18 |
|---|---|
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Target | glucose transporter proteins, hexokinase, glucose-6-phosphatase |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1994 |
Mechanism of action
Fludeoxyglucose F-18 mimics glucose and is taken up by cells that use glucose for energy. It is transported into cells via glucose transporters and phosphorylated by hexokinase, trapping it inside the cell until dephosphorylated. The amount retained reflects the cell's metabolic rate.
Approved indications
- Oncology - Malignancy Evaluation
- Cardiology - Myocardial Metabolism
- Neurology - Epileptic Seizures
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- DDAVP for Pituitary Adenoma (NA)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Reliability of the Human Brain Connectome (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLUDEOXYGLUCOSE F 18 CI brief — competitive landscape report
- FLUDEOXYGLUCOSE F 18 updates RSS · CI watch RSS